Citadel Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-179,721
| Closed | -$1.13M | – | 6700 |
|
|
2025
Q1 | $1.13M | Buy |
179,721
+107,714
| +150% | +$675K | ﹤0.01% | 3153 |
|
|
2024
Q4 | $585K | Sell |
72,007
-148,396
| -67% | -$1.2M | ﹤0.01% | 3835 |
|
|
2024
Q3 | $3.98M | Buy |
220,403
+141,587
| +180% | +$2.56M | ﹤0.01% | 1951 |
|
|
2024
Q2 | $812K | Sell |
78,816
-46,829
| -37% | -$482K | ﹤0.01% | 3260 |
|
|
2024
Q1 | $1.33M | Buy |
125,645
+114,112
| +989% | +$1.21M | ﹤0.01% | 2880 |
|
|
2023
Q4 | $105K | Sell |
11,533
-264,194
| -96% | -$2.41M | ﹤0.01% | 4857 |
|
|
2023
Q3 | $2.86M | Buy |
275,727
+258,812
| +1,530% | +$2.68M | ﹤0.01% | 2070 |
|
|
2023
Q2 | $242K | Sell |
16,915
-171,569
| -91% | -$2.46M | ﹤0.01% | 4283 |
|
|
2023
Q1 | $1.35M | Buy |
188,484
+186,731
| +10,652% | +$1.33M | ﹤0.01% | 2895 |
|
|
2022
Q4 | $19.7K | Buy |
+1,753
| New | +$19.7K | ﹤0.01% | 5558 |
|
|
2022
Q3 | – | Sell |
-25,012
| Closed | -$212K | – | 6486 |
|
|
2022
Q2 | $212K | Buy |
+25,012
| New | +$212K | ﹤0.01% | 4956 |
|
|
2022
Q1 | – | Sell |
-11,466
| Closed | -$226K | – | 6922 |
|
|
2021
Q4 | $226K | Sell |
11,466
-7,944
| -41% | -$157K | ﹤0.01% | 5384 |
|
|
2021
Q3 | $623K | Sell |
19,410
-60,964
| -76% | -$1.96M | ﹤0.01% | 4295 |
|
|
2021
Q2 | $2.72M | Buy |
80,374
+71,833
| +841% | +$2.43M | ﹤0.01% | 2872 |
|
|
2021
Q1 | $321K | Sell |
8,541
-3,535
| -29% | -$133K | ﹤0.01% | 4977 |
|
|
2020
Q4 | $401K | Buy |
12,076
+5,360
| +80% | +$178K | ﹤0.01% | 4025 |
|
|
2020
Q3 | $246K | Buy |
+6,716
| New | +$246K | ﹤0.01% | 3968 |
|
|
2020
Q2 | – | Sell |
-11,948
| Closed | -$308K | – | 5131 |
|
|
2020
Q1 | $308K | Buy |
+11,948
| New | +$308K | ﹤0.01% | 3771 |
|